Brookside invests in SummitReheis

Brookside Mezzanine Partners has made an undisclosed investment in SummitReheis, a portfolio company of One Rock Capital Partners. Based in Huguenot, NY, Summit is a maker of active ingredients for antiperspirants.

PRESS RELEASE

Brookside Mezzanine Partners is pleased to announce its investment in Summit Research Labs, Inc. d/b/a SummitReheis (“Summit”). Headquartered in Huguenot, NY, Summit is the leading global manufacturer of active ingredients for antiperspirants. With an unparalleled knowledge base and experience to match, Summit has been driving innovation in antiperspirant technology since the mid-1900s and has built a solid reputation around the world for leadership, innovation and customer satisfaction.

Brookside Mezzanine Partners provided subordinated debt to partially refinance existing indebtedness of Summit, a portfolio company of One Rock Capital Partners, LLC (“One Rock”). One Rock is a leading middle-market private equity firm with offices in New York, NY and Los Angeles, CA.

About Brookside Mezzanine Partners
Founded in 2001, Brookside Mezzanine Partners manages in excess of $500 million across three mezzanine funds. The Firm is a leading provider of subordinated debt and minority equity capital to small and mid-sized companies throughout the United States. We invest in both sponsored and non-sponsored transactions and provide junior capital and unitranche financing to support buyouts, leveraged recapitalizations, strategic acquisitions, dividends and growth capital.

Please contact us or visit our website at www.brooksidemp.com for additional information.